These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 8230282

  • 1. Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole.
    Rigas JR, Francis PA, Muindi JR, Kris MG, Huselton C, DeGrazia F, Orazem JP, Young CW, Warrell RP.
    J Natl Cancer Inst; 1993 Dec 01; 85(23):1921-6. PubMed ID: 8230282
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia.
    Miller WH, Jakubowski A, Tong WP, Miller VA, Rigas JR, Benedetti F, Gill GM, Truglia JA, Ulm E, Shirley M.
    Blood; 1995 Jun 01; 85(11):3021-7. PubMed ID: 7756637
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia.
    Schwartz EL, Hallam S, Gallagher RE, Wiernik PH.
    Biochem Pharmacol; 1995 Sep 28; 50(7):923-8. PubMed ID: 7575674
    [Abstract] [Full Text] [Related]

  • 7. Variability in the oral bioavailability of all-trans-retinoic acid.
    Adamson PC, Pitot HC, Balis FM, Rubin J, Murphy RF, Poplack DG.
    J Natl Cancer Inst; 1993 Jun 16; 85(12):993-6. PubMed ID: 8388479
    [Abstract] [Full Text] [Related]

  • 8. Clinical pharmacology of all-trans retinoic acid.
    Muindi JR, Young CW, Warrell RP.
    Leukemia; 1994 Nov 16; 8(11):1807-12. PubMed ID: 7967726
    [Abstract] [Full Text] [Related]

  • 9. Retinoid metabolism and transplacental pharmacokinetics in the cynomolgus monkey following a nonteratogenic dosing regimen with all-trans-retinoic acid.
    Tzimas G, Nau H, Hendrickx AG, Peterson PE, Hummler H.
    Teratology; 1996 Nov 16; 54(5):255-65. PubMed ID: 9035347
    [Abstract] [Full Text] [Related]

  • 10. Clinical pharmacology of all-trans retinoic acid.
    Muindi JR, Young CW, Warrell RP.
    Leukemia; 1994 Nov 16; 8 Suppl 3():S16-21. PubMed ID: 7808019
    [Abstract] [Full Text] [Related]

  • 11. Clinical relevance of all-trans retinoic acid pharmacokinetics and its modulation in acute promyelocytic leukemia.
    Lazzarino M, Regazzi MB, Corso A.
    Leuk Lymphoma; 1996 Nov 16; 23(5-6):539-43. PubMed ID: 9031084
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia.
    Lefebvre P, Thomas G, Gourmel B, Agadir A, Castaigne S, Dreux C, Degos L, Chomienne C.
    Leukemia; 1991 Dec 16; 5(12):1054-8. PubMed ID: 1774953
    [Abstract] [Full Text] [Related]

  • 13. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia.
    Muindi J, Frankel SR, Miller WH, Jakubowski A, Scheinberg DA, Young CW, Dmitrovsky E, Warrell RP.
    Blood; 1992 Jan 15; 79(2):299-303. PubMed ID: 1309668
    [Abstract] [Full Text] [Related]

  • 14. Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice.
    Achkar CC, Bentel JM, Boylan JF, Scher HI, Gudas LJ, Miller WH.
    Drug Metab Dispos; 1994 Jan 15; 22(3):451-8. PubMed ID: 8070324
    [Abstract] [Full Text] [Related]

  • 15. Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats.
    Van Wauwe JP, Coene MC, Goossens J, Cools W, Monbaliu J.
    J Pharmacol Exp Ther; 1990 Jan 15; 252(1):365-9. PubMed ID: 2299598
    [Abstract] [Full Text] [Related]

  • 16. Constitutive expression of cellular retinoic acid binding protein II and lack of correlation with sensitivity to all-trans retinoic acid in acute promyelocytic leukemia cells.
    Zhou DC, Hallam SJ, Lee SJ, Klein RS, Wiernik PH, Tallman MS, Gallagher RE.
    Cancer Res; 1998 Dec 15; 58(24):5770-6. PubMed ID: 9865735
    [Abstract] [Full Text] [Related]

  • 17. Regulation of a highly specific retinoic acid-4-hydroxylase (CYP26A1) enzyme and all-trans-retinoic acid metabolism in human intestinal, liver, endothelial, and acute promyelocytic leukemia cells.
    Ozpolat B, Mehta K, Lopez-Berestein G.
    Leuk Lymphoma; 2005 Oct 15; 46(10):1497-506. PubMed ID: 16194896
    [Abstract] [Full Text] [Related]

  • 18. Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein.
    Kizaki M, Ueno H, Yamazoe Y, Shimada M, Takayama N, Muto A, Matsushita H, Nakajima H, Morikawa M, Koeffler HP, Ikeda Y.
    Blood; 1996 Jan 15; 87(2):725-33. PubMed ID: 8555497
    [Abstract] [Full Text] [Related]

  • 19. Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer.
    Rizvi NA, Marshall JL, Ness E, Yoe J, Gill GM, Truglia JA, Loewen GR, Jaunakais D, Ulm EH, Hawkins MJ.
    Clin Cancer Res; 1998 Jun 15; 4(6):1437-42. PubMed ID: 9626460
    [Abstract] [Full Text] [Related]

  • 20. Elevated plasma lipid peroxide content correlates with rapid plasma clearance of all-trans-retinoic acid in patients with advanced cancer.
    Muindi JF, Scher HI, Rigas JR, Warrell RP, Young CW.
    Cancer Res; 1994 Apr 15; 54(8):2125-8. PubMed ID: 8174117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.